Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Dare Bioscience appoints Sophia Ononye-Onyia to board of directors » 08:20
04/19/21
04/19
08:20
04/19/21
08:20
DARE

Dare Bioscience

$1.40 /

-0.095 (-6.35%)

Dare Bioscience announced…

Dare Bioscience announced the appointment of Sophia N. Ononye-Onyia, PhD MPH MBA to its Board of Directors. Dr. Ononye-Onyia is the founder and CEO of The Sophia Consulting Firm, which provides strategic marketing and communications consulting services to pharmaceutical, biotech and health tech companies.

ShowHide Related Items >><<
DARE Dare Bioscience
$1.40 /

-0.095 (-6.35%)

DARE Dare Bioscience
$1.40 /

-0.095 (-6.35%)

03/31/21 Roth Capital
Dare Bioscience reaffirmed as top 2021 pick at Roth Capital
12/18/20 H.C. Wainwright
Dare Bioscience initiated with a Buy at H.C. Wainwright
12/07/20 Roth Capital
Dare Bioscience price target raised to $9 from $7 at Roth Capital
09/10/20 Roth Capital
Dare Bioscience resumed with a Buy at Roth Capital
DARE Dare Bioscience
$1.40 /

-0.095 (-6.35%)

Friday
Conference/Events
Inovio management to meet virtually with Oppenheimer » 04:55
04/16/21
04/16
04:55
04/16/21
04:55
INO

Inovio

$9.02 /

+0.17 (+1.92%)

Virtual Meeting to be…

Virtual Meeting to be held on April 16 hosted by Oppenheimer.

ShowHide Related Items >><<
INO Inovio
$9.02 /

+0.17 (+1.92%)

INO Inovio
$9.02 /

+0.17 (+1.92%)

03/23/21
Fly Intel: Top five analyst initiations
03/23/21 BofA
Inovio initiated with a Neutral at BofA
03/02/21 Piper Sandler
Piper lowers Inovio target to $7 after 'decidedly negative' update
02/11/21 Oppenheimer
Opco starts DNA medicines 'disruptor' Inovio with buy, $35 price target
INO Inovio
$9.02 /

+0.17 (+1.92%)

  • 21
    Jan
INO Inovio
$9.02 /

+0.17 (+1.92%)

INO Inovio
$9.02 /

+0.17 (+1.92%)

Thursday
Options
Unusually active option classes on open April 15th » 09:40
04/15/21
04/15
09:40
04/15/21
09:40
HPE

HP Enterprise

$15.78 /

+ (+0.00%)

, GSK

GlaxoSmithKline

$36.12 /

+ (+0.00%)

, INO

Inovio

$8.85 /

+ (+0.00%)

, MLCO

Melco Resorts & Entertainment

$19.53 /

+ (+0.00%)

, BX

Blackstone

$78.01 /

+ (+0.00%)

, SPCE

Virgin Galactic

$26.65 /

+ (+0.00%)

, TSM

TSMC

$120.87 /

+ (+0.00%)

, AI

C3.ai

$68.41 /

-0.07 (-0.10%)

, V

Visa

$222.14 /

+ (+0.00%)

, DOCU

DocuSign

$225.45 /

+ (+0.00%)

Unusual total active…

Unusual total active option classes on open include: Hewlett Packard Enterprise (HPE), GlaxoSmithKline (GSK), Inovio (INO), Melco Resorts (MLCO), Blackstone (BX), Virgin Galactic (SPCE), Taiwan Semi (TSM), C3 AI (AI), Visa (V), and DocuSign (DOCU).

ShowHide Related Items >><<
V Visa
$222.14 /

+ (+0.00%)

TSM TSMC
$120.87 /

+ (+0.00%)

SPCE Virgin Galactic
$26.65 /

+ (+0.00%)

MLCO Melco Resorts & Entertainment
$19.53 /

+ (+0.00%)

INO Inovio
$8.85 /

+ (+0.00%)

HPE HP Enterprise
$15.78 /

+ (+0.00%)

GSK GlaxoSmithKline
$36.12 /

+ (+0.00%)

DOCU DocuSign
$225.45 /

+ (+0.00%)

BX Blackstone
$78.01 /

+ (+0.00%)

AI C3.ai
$68.41 /

-0.07 (-0.10%)

HPE HP Enterprise
$15.78 /

+ (+0.00%)

04/08/21 Morgan Stanley
HP Enterprise price target raised to $17 from $15.50 at Morgan Stanley
03/26/21 JPMorgan
HP Enterprise price target raised to $18 from $17 at JPMorgan
03/10/21
Fly Intel: Top five analyst upgrades
03/10/21 Daiwa
HP Enterprise upgraded to Outperform from Neutral at Daiwa
GSK GlaxoSmithKline
$36.12 /

+ (+0.00%)

03/23/21
Fly Intel: Top five analyst downgrades
03/23/21 SVB Leerink
SVB Leerink moving to sidelines on Alexion, five others on industry concerns
03/23/21 SVB Leerink
GlaxoSmithKline downgraded to Market Perform from Outperform at SVB Leerink
03/08/21 JPMorgan
JPMorgan double downgrades AnaptysBio back to Underweight after trial miss
INO Inovio
$8.85 /

+ (+0.00%)

03/23/21
Fly Intel: Top five analyst initiations
03/23/21 BofA
Inovio initiated with a Neutral at BofA
03/02/21 Piper Sandler
Piper lowers Inovio target to $7 after 'decidedly negative' update
02/11/21 Oppenheimer
Opco starts DNA medicines 'disruptor' Inovio with buy, $35 price target
MLCO Melco Resorts & Entertainment
$19.53 /

+ (+0.00%)

02/25/21 CLSA
Melco Resorts & Entertainment upgraded to Outperform from Underperform at CLSA
01/07/21 Macquarie
Melco Resorts & Entertainment downgraded to Neutral from Outperform at Macquarie
11/17/20 JPMorgan
Melco Resorts & Entertainment price target raised to $25 from $23 at JPMorgan
11/05/20 Roth Capital
Roth Capital trims price target on 'go-to Macau name' Melco Resorts to $30
BX Blackstone
$78.01 /

+ (+0.00%)

04/12/21 Barclays
Blackstone price target raised to $85 from $75 at Barclays
04/09/21 Deutsche Bank
Blackstone price target raised to $66 from $61 at Deutsche Bank
03/19/21
Fly Intel: Top five analyst downgrades
03/18/21 Oppenheimer
Blackstone downgraded to Perform on valuation at Oppenheimer
SPCE Virgin Galactic
$26.65 /

+ (+0.00%)

04/12/21 Bernstein
Virgin Galactic initiated with a Market Perform at Bernstein
03/16/21 Truist
Truist starts 'uniquely positioned' Virgin Galactic at Buy with $50 price target
03/16/21 Truist
Virgin Galactic initiated with a Buy at Truist
03/03/21 BofA
Virgin Galactic price target raised to $50 from $35 at BofA
TSM TSMC
$120.87 /

+ (+0.00%)

04/12/21
Fly Intel: Top five analyst initiations
04/12/21 Atlantic Equities
TSMC initiated with a Neutral at Atlantic Equities
04/01/21 DA Davidson
Onto Innovation price target raised to $80 from $75 at DA Davidson
03/29/21 Citi
TSMC recent selloff brings 'enhanced buying opportunity,' says Citi
AI C3.ai
$68.41 /

-0.07 (-0.10%)

03/02/21 Canaccord
C3.ai price target lowered to $120 from $140 at Canaccord
01/04/21 KeyBanc
C3.ai initiated with a Sector Weight at KeyBanc
01/04/21 Wedbush
Wedbush bullish on C3.ai, initiates with an Outperform
01/04/21 Canaccord
C3.ai initiated with a Hold at Canaccord
V Visa
$222.14 /

+ (+0.00%)

03/19/21 JPMorgan
Visa has 'navigated heavy regulatory oversight' before, says JPMorgan
03/19/21 Wells Fargo
Visa selloff on WSJ story likely a buying opportunity, says Wells Fargo
03/19/21 Barclays
Visa, MasterCard facing new DOJ scrutiny on debt practices, says Barclays
03/16/21 Morgan Stanley
Visa price target raised to $253 from $233 at Morgan Stanley
DOCU DocuSign
$225.45 /

+ (+0.00%)

04/08/21 BofA
BofA reinstates DocuSign at Buy with $250 price target
04/08/21 BofA
DocuSign reinstated with a Buy at BofA
03/29/21 Daiwa
DocuSign initiated with a Buy at Daiwa
03/25/21 DA Davidson
DocuSign still confident in reaching $5B or more in revenue, says DA Davidson
V Visa
$222.14 /

+ (+0.00%)

TSM TSMC
$120.87 /

+ (+0.00%)

SPCE Virgin Galactic
$26.65 /

+ (+0.00%)

MLCO Melco Resorts & Entertainment
$19.53 /

+ (+0.00%)

INO Inovio
$8.85 /

+ (+0.00%)

HPE HP Enterprise
$15.78 /

+ (+0.00%)

GSK GlaxoSmithKline
$36.12 /

+ (+0.00%)

DOCU DocuSign
$225.45 /

+ (+0.00%)

BX Blackstone
$78.01 /

+ (+0.00%)

AI C3.ai
$68.41 /

-0.07 (-0.10%)

  • 21
    Jan
  • 09
    Dec
  • 13
    Oct
  • 06
    Aug
  • 03
    Jun
  • 20
    May
V Visa
$222.14 /

+ (+0.00%)

TSM TSMC
$120.87 /

+ (+0.00%)

SPCE Virgin Galactic
$26.65 /

+ (+0.00%)

GSK GlaxoSmithKline
$36.12 /

+ (+0.00%)

DOCU DocuSign
$225.45 /

+ (+0.00%)

BX Blackstone
$78.01 /

+ (+0.00%)

V Visa
$222.14 /

+ (+0.00%)

TSM TSMC
$120.87 /

+ (+0.00%)

SPCE Virgin Galactic
$26.65 /

+ (+0.00%)

MLCO Melco Resorts & Entertainment
$19.53 /

+ (+0.00%)

INO Inovio
$8.85 /

+ (+0.00%)

HPE HP Enterprise
$15.78 /

+ (+0.00%)

GSK GlaxoSmithKline
$36.12 /

+ (+0.00%)

DOCU DocuSign
$225.45 /

+ (+0.00%)

BX Blackstone
$78.01 /

+ (+0.00%)

AI C3.ai
$68.41 /

-0.07 (-0.10%)

V Visa
$222.14 /

+ (+0.00%)

TSM TSMC
$120.87 /

+ (+0.00%)

SPCE Virgin Galactic
$26.65 /

+ (+0.00%)

MLCO Melco Resorts & Entertainment
$19.53 /

+ (+0.00%)

INO Inovio
$8.85 /

+ (+0.00%)

HPE HP Enterprise
$15.78 /

+ (+0.00%)

DOCU DocuSign
$225.45 /

+ (+0.00%)

BX Blackstone
$78.01 /

+ (+0.00%)

AI C3.ai
$68.41 /

-0.07 (-0.10%)

Hot Stocks
Inovio's COVID-19 vaccine candidate shows response against all tested variants » 08:10
04/15/21
04/15
08:10
04/15/21
08:10
INO

Inovio

$8.85 /

+0.115 (+1.32%)

Inovio announced the…

Inovio announced the results of a study focusing on the human immune responses induced by Inovio's DNA vaccine candidate for COVID-19, INO-4800, against variants of concern. The results showed that INO-4800 induced a robust T cell response against all spike protein variants tested, which the company believes will be key in providing protection against SARS-CoV-2 variants, in addition to providing similar levels of neutralizing activity against both the UK and Brazilian variants as those against the original strain. The study has been submitted for peer review. The study showed the T cell responses induced by INO-4800 vaccination were fully maintained against the UK, South African and Brazilian variants when compared to the T cell responses to the original Wuhan strain. The neutralization levels of INO-4800 against South Africa and UK variants were reduced to the levels similar to the previous reports of mRNA or viral vector vaccines. Furthermore, despite recent reports showing a reduction in neutralizing activity against the Brazilian variant by the mRNA or viral vector vaccines, INO-4800 generated robust neutralizing antibodies at levels against Brazilian variant which were comparable to those against the Wuhan strain. Collectively, the studies showcase how the combination of robust T cell responses in conjunction with neutralizing antibody responses provide an important defense against both emerging and potential future viral variants, exhibiting broad protection against the virus and less impacted by the mutational changes a virus may undergo.

ShowHide Related Items >><<
INO Inovio
$8.85 /

+0.115 (+1.32%)

INO Inovio
$8.85 /

+0.115 (+1.32%)

03/23/21
Fly Intel: Top five analyst initiations
03/23/21 BofA
Inovio initiated with a Neutral at BofA
03/02/21 Piper Sandler
Piper lowers Inovio target to $7 after 'decidedly negative' update
02/11/21 Oppenheimer
Opco starts DNA medicines 'disruptor' Inovio with buy, $35 price target
INO Inovio
$8.85 /

+0.115 (+1.32%)

  • 21
    Jan
INO Inovio
$8.85 /

+0.115 (+1.32%)

INO Inovio
$8.85 /

+0.115 (+1.32%)

Wednesday
Conference/Events
Inovio management to meet virtually with Oppenheimer » 14:58
04/14/21
04/14
14:58
04/14/21
14:58
INO

Inovio

$8.97 /

+0.235 (+2.69%)

Virtual Meeting to be…

Virtual Meeting to be held on April 16 hosted by Oppenheimer.

ShowHide Related Items >><<
INO Inovio
$8.97 /

+0.235 (+2.69%)

INO Inovio
$8.97 /

+0.235 (+2.69%)

03/23/21
Fly Intel: Top five analyst initiations
03/23/21 BofA
Inovio initiated with a Neutral at BofA
03/02/21 Piper Sandler
Piper lowers Inovio target to $7 after 'decidedly negative' update
02/11/21 Oppenheimer
Opco starts DNA medicines 'disruptor' Inovio with buy, $35 price target
INO Inovio
$8.97 /

+0.235 (+2.69%)

  • 21
    Jan
INO Inovio
$8.97 /

+0.235 (+2.69%)

INO Inovio
$8.97 /

+0.235 (+2.69%)

Over a week ago
Recommendations
Agile Therapeutics transferred with an Outperform at RBC Capital » 16:45
04/06/21
04/06
16:45
04/06/21
16:45
AGRX

Agile Therapeutics

$2.07 /

+0.01 (+0.49%)

RBC Capital transferred…

RBC Capital transferred coverage of Agile Therapeutics to analyst Daniel Busby, and kept an Outperform rating and $8 price target on the stock.

ShowHide Related Items >><<
AGRX Agile Therapeutics
$2.07 /

+0.01 (+0.49%)

AGRX Agile Therapeutics
$2.07 /

+0.01 (+0.49%)

12/08/20 H.C. Wainwright
Agile Therapeutics price target raised to $7 from $6 at H.C. Wainwright
09/22/20 H.C. Wainwright
H.C. Wainwright says Agile coverage, access for Twirla launch underappreciated
AGRX Agile Therapeutics
$2.07 /

+0.01 (+0.49%)

AGRX Agile Therapeutics
$2.07 /

+0.01 (+0.49%)

Recommendations
Dare Bioscience reaffirmed as top 2021 pick at Roth Capital » 09:42
03/31/21
03/31
09:42
03/31/21
09:42
DARE

Dare Bioscience

$1.69 /

+ (+0.00%)

Roth Capital analyst…

Roth Capital analyst Zegbeh Jallah reaffirmed Dare Bioscience as a top 2021 pick following the company's Q4 results. The New Drug Application submission for DARE-BV1 in bacterial vaginosis remains on track for Q2, "teeing up" for a potential 2021 FDA action date and Dare's announcement of the commercial partnership structure, Jallah tells investors in a research note. The analyst sees a "catalyst-rich year" in 2021 and maintains a Buy rating on Dare Bioscience with a $9 price target.

ShowHide Related Items >><<
DARE Dare Bioscience
$1.69 /

+ (+0.00%)

DARE Dare Bioscience
$1.69 /

+ (+0.00%)

12/18/20 H.C. Wainwright
Dare Bioscience initiated with a Buy at H.C. Wainwright
12/07/20 Roth Capital
Dare Bioscience price target raised to $9 from $7 at Roth Capital
09/10/20 Roth Capital
Dare Bioscience resumed with a Buy at Roth Capital
04/27/20 Brookline
Dare Bioscience initiated with a Buy at Brookline
DARE Dare Bioscience
$1.69 /

+ (+0.00%)

Syndicate
Dare Bioscience files $200M mixed securities shelf  17:09
03/30/21
03/30
17:09
03/30/21
17:09
DARE

Dare Bioscience

$1.69 /

+0.01 (+0.60%)

 
ShowHide Related Items >><<
DARE Dare Bioscience
$1.69 /

+0.01 (+0.60%)

DARE Dare Bioscience
$1.69 /

+0.01 (+0.60%)

12/18/20 H.C. Wainwright
Dare Bioscience initiated with a Buy at H.C. Wainwright
12/07/20 Roth Capital
Dare Bioscience price target raised to $9 from $7 at Roth Capital
09/10/20 Roth Capital
Dare Bioscience resumed with a Buy at Roth Capital
04/27/20 Brookline
Dare Bioscience initiated with a Buy at Brookline
DARE Dare Bioscience
$1.69 /

+0.01 (+0.60%)

Hot Stocks
Dare Bioscience announces 2021 key portfolio objectives » 08:16
03/30/21
03/30
08:16
03/30/21
08:16
DARE

Dare Bioscience

$1.68 /

-0.06 (-3.46%)

2021 Key Portfolio…

2021 Key Portfolio Objectives: DARE-BV1: New Drug Application submission and strategic commercialization agreement. Sildenafil Cream, 3.6%: Phase 2b clinical study commencement and topline data. Ovaprene: Investigational Device Exemption submission. DARE-HRT1: Phase 1 clinical study topline data. DARE-VVA1: Initiation of Phase 1 clinical study.

ShowHide Related Items >><<
DARE Dare Bioscience
$1.68 /

-0.06 (-3.46%)

DARE Dare Bioscience
$1.68 /

-0.06 (-3.46%)

12/18/20 H.C. Wainwright
Dare Bioscience initiated with a Buy at H.C. Wainwright
12/07/20 Roth Capital
Dare Bioscience price target raised to $9 from $7 at Roth Capital
09/10/20 Roth Capital
Dare Bioscience resumed with a Buy at Roth Capital
04/27/20 Brookline
Dare Bioscience initiated with a Buy at Brookline
DARE Dare Bioscience
$1.68 /

-0.06 (-3.46%)

Earnings
Dare Bioscience reports 2020 EPS (91c), consensus (81c) » 08:14
03/30/21
03/30
08:14
03/30/21
08:14
DARE

Dare Bioscience

$1.68 /

-0.06 (-3.46%)

"Despite the unique…

"Despite the unique challenges posed during 2020, we achieved two important corporate firsts in 2020. We started the year in January by announcing our first commercial partnership agreement, with Bayer for Ovaprene commercialization rights. We believe that this partnership not only validates the Ovaprene commercial opportunity and allows Dare to benefit from Bayer's expertise in development, regulatory affairs and commercialization of first-in-category contraceptive products for women, but, with up to $310 million in commercial milestone payments, plus double-digit, tiered royalties on net sales, that it will also provide capital to support broader portfolio objectives. Then, we ended the year in December with the completion of our first portfolio Phase 3 study - specifically, we announced positive topline data from the DARE-BVFREE Phase 3 study of DARE-BV1 for the treatment of bacterial vaginosis, positioning Dare for our first NDA submission," said Sabrina Martucci Johnson, President and CEO of Dare Bioscience. "The advances in 2020 across the portfolio set the stage for meaningful portfolio objectives in 2021."

ShowHide Related Items >><<
DARE Dare Bioscience
$1.68 /

-0.06 (-3.46%)

DARE Dare Bioscience
$1.68 /

-0.06 (-3.46%)

12/18/20 H.C. Wainwright
Dare Bioscience initiated with a Buy at H.C. Wainwright
12/07/20 Roth Capital
Dare Bioscience price target raised to $9 from $7 at Roth Capital
09/10/20 Roth Capital
Dare Bioscience resumed with a Buy at Roth Capital
04/27/20 Brookline
Dare Bioscience initiated with a Buy at Brookline
DARE Dare Bioscience
$1.68 /

-0.06 (-3.46%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.